Objective response of multiple myeloma to cyclosporin a

Peter H. Wiernik, Janice P. Dutcher, Andrea N. Leaf, Zenghua Liao, Elisabeth M. Paietta, David L. Rosenstreich

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A, one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.

Original languageEnglish (US)
Pages (from-to)167-170
Number of pages4
JournalLeukemia and Lymphoma
Volume16
Issue number1-2
DOIs
StatePublished - 1994

Fingerprint

Multiple Myeloma
Cyclosporine
beta 2-Microglobulin
Interleukin-6
Drug Therapy
Therapeutics
Serum

Keywords

  • Cyclosporin therapy
  • Myeloma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Objective response of multiple myeloma to cyclosporin a. / Wiernik, Peter H.; Dutcher, Janice P.; Leaf, Andrea N.; Liao, Zenghua; Paietta, Elisabeth M.; Rosenstreich, David L.

In: Leukemia and Lymphoma, Vol. 16, No. 1-2, 1994, p. 167-170.

Research output: Contribution to journalArticle

Wiernik, Peter H. ; Dutcher, Janice P. ; Leaf, Andrea N. ; Liao, Zenghua ; Paietta, Elisabeth M. ; Rosenstreich, David L. / Objective response of multiple myeloma to cyclosporin a. In: Leukemia and Lymphoma. 1994 ; Vol. 16, No. 1-2. pp. 167-170.
@article{6cf85f8f1f2f42abbffd390eea7bd419,
title = "Objective response of multiple myeloma to cyclosporin a",
abstract = "Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A, one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.",
keywords = "Cyclosporin therapy, Myeloma",
author = "Wiernik, {Peter H.} and Dutcher, {Janice P.} and Leaf, {Andrea N.} and Zenghua Liao and Paietta, {Elisabeth M.} and Rosenstreich, {David L.}",
year = "1994",
doi = "10.3109/10428199409114154",
language = "English (US)",
volume = "16",
pages = "167--170",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Objective response of multiple myeloma to cyclosporin a

AU - Wiernik, Peter H.

AU - Dutcher, Janice P.

AU - Leaf, Andrea N.

AU - Liao, Zenghua

AU - Paietta, Elisabeth M.

AU - Rosenstreich, David L.

PY - 1994

Y1 - 1994

N2 - Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A, one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.

AB - Two patients with advanced multiple myeloma were treated with oral low-dose cyclosporin A, one without other therapy and one in conjunction with chemotherapy to which the patient had been previously unresponsive. Both patients had objective laboratory and clinical responses. In the patient treated with cyclosporin A alone, decreasing serum IL-6 and beta-2-microglobulin levels fell as the clinical response evolved. Cyclosporin A deserves further evaluation in the therapy of multiple myeloma.

KW - Cyclosporin therapy

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=0028578249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028578249&partnerID=8YFLogxK

U2 - 10.3109/10428199409114154

DO - 10.3109/10428199409114154

M3 - Article

C2 - 7696923

AN - SCOPUS:0028578249

VL - 16

SP - 167

EP - 170

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -